alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

Dr. Beth Bell (ACIP, WG Chair)

Dr. Tonya Villafana (AstraZeneca)

11:15

11:30 COVID-19 Epidemology among Children

Pediatric COVID-19 Clinical Trials

Dr. Angela Campbell (CDC/NCIRD)

Dr. Emily Erbelding (NIH)

12:30

1:00 Vaccine Safety Technical Subgroup (VaST) introduction

COVID-19 Vaccine Safety Update

VaST assessement of safety data

Dr. Grace Lee (ACIP, VaST Co-chair)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Grace Lee (ACIP, VaST Co-chair)

2:30

2:45 Update on COVID-19 Vaccine Administration 

COVID-19 Vaccine Effectiveness Studies

Work Group Interpretation and Next Steps

Dr. Amanda Cohn (CDC/NCIRD)

Dr. Katherine Fleming-Dutra (CDC/NCIRD)

Dr. Sara Oliver (CDC/NCIRD)

4:15

4:30

5:00

Acronyms

CDC

CMS

COVID-19

EtR

FDA

GRADE

HRSA

IHS

NCHHSTP

NCIRD

NCEZID

NIAID

OIDP

SARS-CoV-2

WG

WHO

VE

Food and Drug Administration

Grading of Recommendations Assessment, Development and Evaluation

Vaccine Effectiveness

Break

Public comment

Adjourn

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

January 27, 2021

AGENDA ITEM

Wednesday, January 27, 2021

10:00 Welcome & Introductions

Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

AstraZeneca COVID-19 vaccine (AZD1222)

Centers for Disease Control and Prevention

Centers for Medicare and Medicaid Services 

Coronavirus disease 2019

Evidence to Recommendations Framework

Break

Break

Break

Health Resources and Services Administration

Indian Health Service

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Institute of Allergy and Infectious Diseases

Office of Infectious Disease and HIV/AIDS Policy

Severe acute respiratory syndrome coronavirus 

Work Group

World Health Organization
##### 



Exhibit 32.1
 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  
    
    The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September
30, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and
    
    The information contained in such Quarterly Report on Form 10-Q fairly presents, in all
material respects, the financial condition and results of operations of the Company.
 /s/ Thomas L. Monahan IIIThomas L. Monahan IIIChief Executive OfficerNovember 9, 2005/s/ Timothy R. YostTimothy R. YostChief Financial OfficerNovember 9, 2005
 20
No. 11-5496.

#### Donald Stanton Shealey, Petitioner v. United States.

565 U.S. 911, 132 S. Ct. 320,

181 L. Ed. 2d 198,

2011 U.S. LEXIS 5870.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 641 F.3d 627.
The State of TexasAppellee/s

Fourth Court of Appeals

San Antonio, Texas

January 8, 2015

No. 04-14-00100-CR

Edgar Javier GONZALES,

Appellant

v.

THE STATE OF TEXAS,

Appellee

From the 25th Judicial District Court, Guadalupe County, Texas

Trial Court No. 10-2321-CR

William Old, Judge Presiding

ORDER

The State’s Motion for Extension of Time to File Brief is hereby GRANTED. The 

State’s brief is due January 30, 2015.

_________________________________

Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 8th day of January, 2015.

___________________________________

Keith E. Hottle

Clerk of Court
89

Section C: Recommended Funding Levels, by State

Hawaii

Program Intervention Budgets: 2014

Recommended Annual Investment $13.7 million

Deaths in State Caused by Smoking

Annual average smoking-attributable deaths 1,400

Youth aged 0-17 projected to die from smoking 21,400

Annual Costs Incurred in State from Smoking

Total medical $526 million

State Revenue from Tobacco Sales and Settlement

FY 2012 tobacco tax revenue $138.8 million

FY 2012 tobacco settlement payment $48.6 million

Total state revenue from tobacco sales and settlement $187.4 million

Percent Tobacco Revenue to Fund at Recommended Level 7%

Annual Total (Millions) Annual Per Capita

Minimum Recommended Minimum Recommended

I. State and Community Interventions 

Multiple social resources working together will 

have the greatest long-term population impact.

$4.5 $5.6 $3.23 $4.02

II. Mass-Reach Health Communication Interventions 

Media interventions work to prevent smoking initiation, 

promote cessation, and shape social norms.

$1.1 $1.6 $0.79 $1.15

III. Cessation Interventions 

Tobacco use treatment is effective and highly cost-effective. $3.0 $4.7 $2.15 $3.38

IV. Surveillance and Evaluation 

Publicly funded programs should be accountable and 

demonstrate effectiveness.

$0.9 $1.2 $0.62 $0.86

V. Infrastructure, Administration, and Management 

Complex, integrated programs require experienced 

staff to provide fiscal management, accountability, 

and coordination.

$0.4 $0.6 $0.31 $0.43

TOTAL $9.9 $13.7 $7.10 $9.84

Note: A justification for each program element and the rationale for the budget estimates are provided in Section A. The funding estimates presented are based on adjustments for changes in population and cost-of-living increases since Best Practices—2007 was published. The actual 

funding required for implementing programs will vary depending on state characteristics, such as prevalence of tobacco use, sociodemographic 

factors, and other factors. See Appendix E for data sources on deaths, costs, revenue, and state-specific factors. 

Centers for Disease Control and Prevention • Office on Smoking and Health

www.cdc.gov/tobacco • tobaccoinfo@cdc.gov • 1 (800) CDC-INFO or 1 (800) 232-4636 

2014
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          FEB-28-2000
<PERIOD-END>                               NOV-30-1999
<CASH>                                           5,263
<SECURITIES>                                         0
<RECEIVABLES>                                      525
<ALLOWANCES>                                         0
<INVENTORY>                                     12,790
<CURRENT-ASSETS>                                18,053
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  26,838
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        12,841
<OTHER-SE>                                      13,997
<TOTAL-LIABILITY-AND-EQUITY>                    26,838
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 5,882
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (5,882)
<INCOME-TAX>                                     2,650
<INCOME-CONTINUING>                            (3,232)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,232)
<EPS-BASIC>                                     (0.01)
<EPS-DILUTED>                                   (0.01)


</TABLE>
```

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the
undersigned officer of Scotia Pacific Company LLC, a Delaware limited liability
company (the "Company"), does hereby certify that:

         (a) the accompanying Quarterly Report on Form 10-Q for the quarter
ended March 31, 2004 of the Company (the "Report") fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

         (b) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: May 10, 2004

                                   /S/              ROBERT E. MANNE
                                 ------------------------------------------------
                                                Robert E. Manne
                                            Chief Executive Officer

The foregoing certification is being furnished solely pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter
63 of Title 18, United States Code).
```
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER OF ABATEMENT

Appellate case name: Lenin Saldado Lopez v. The State of Texas

Appellate case number: 01-13-01079-CR

Trial court case number: 1403196

Trial court: 228th District Court of Harris County

On May 12, 2014, the Court granted an extension to file appellants brief until June 12, 

2014, with no further extensions and an explanation that if no brief was filed, the appeal would 

be abated. No brief has been filed.

On June 13, 2014, appellant filed his “Final Motion for Extension for 14 Days and 

Request Not to Abate Due to Confusion.”

The motion is GRANTED, in part. Appellant’s brief is due June 27, 2014. No further 

extensions will be considered or granted.

The appeal is abated, treated as a closed case, and removed from this Court’s active 

docket. The appeal will be reinstated on this Court’s active docket immediately upon filing of 

appellant’s brief in this Court, and appellee’s brief will be due within 30 days of the date 

appellant’s brief is filed. See TEX. R. APP. P. 38.6(b).

It is so ORDERED.

Judge’s signature: /s/ Harvey Brown

 Acting individually  Acting for the Court

Date: June 17, 2014
No. 11-361.

#### Rudolph Alexander, Petitioner v. Ohio State University College of Social Work, et al.

565 U.S. 979, 132 S. Ct. 528,

181 L. Ed. 2d 352,

2011 U.S. LEXIS 7907.

October 31, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.

Same case below, 429 Fed. Appx. 481.
Description of Compensatory Arrangements



 Exhibit 10.21  
  
 DESCRIPTION OF COMPENSATORY ARRANGEMENTS 
 BETWEEN VARIAN, INC. AND NON-EMPLOYEE DIRECTORS 
  
 Each director (other than the Chairman of the Board) who is not a Company employee is paid an annual retainer fee of $30,000. Each non-employee director
is also paid $2,000 for each Board meeting attended in person, $1,000 for each Board meeting attended by telephone and $1,000 for each Board committee meeting attended in person or by telephone (effective following the next annual meeting of the
Company’s stockholders, scheduled to be held on February 3, 2005, this committee meeting fee will be increased to $1,500). The director who chairs the Audit Committee of the Board is paid an additional annual retainer fee of $15,000. The
directors who chair the Compensation and the Nominating and Governance Committees of the Board are each paid an additional annual retainer fee of $5,000 (effective following the next annual meeting of the Company’s stockholders, scheduled to be
held on February 3, 2005, this additional annual retainer fee will be increased to $7,500). 
  
 The non-employee Chairman of the Board is paid an annual retainer fee of $120,000 (in lieu of any other annual retainer, committee chair or attendance fees). 
  
 Directors may elect to receive, in lieu of all or a portion of the retainer,
chairman or meeting fees described above, shares of the Company’s common stock based on the fair market value of the Company’s common stock on the date the fees would have been paid. 
  
 Under the Company’s Omnibus Stock Plan, each director who is not a
Company employee receives upon initial appointment or election to the Board a nonqualified stock option to acquire 10,000 shares of the Company’s common stock, and receives annually thereafter a nonqualified stock option to acquire 5,000 shares
of the Company’s common stock. In lieu of these grants, the non-employee Chairman of the Board receives upon initial appointment as such a nonqualified stock option to acquire 50,000 shares of the Company’s common stock. All such stock
options are granted with an exercise price equal to the fair market value of the Company’s common stock on the grant date, are vested and exercisable beginning on the grant date and have a ten-year term. 
  
 Each director is reimbursed for all reasonable out-of-pocket expenses that
such director and his or her spouse incurs attending Board meetings and functions.
# Mumps Vaccine-Preventable Diseases Infographic

Minus

Mumps. More than just swollen glands.
        - Printer file (8.33′′ x 37.67′′) [1 page]
        - Read text equivalent (for Section 508 access)
        - Fact sheet for parents: mumps and the vaccine (shot) to prevent it
        - Learn more about how mumps spreads and see photos of mumps
        - 14 diseases you almost forgot about (thanks to vaccines)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

##  Mumps (Text Version)

More than just swollen glands

**Mumps can be dangerous**

[Illustration of head profile with brain and ear]

Before there was a vaccine, mumps was one of the most common causes of:
        - Deafness and
        - Meningitis (infection of the brain and spinal cord covering) in childhood.

Mumps can also lead to
        - Encephalitis (swelling of the brain) in some children.

**Symptoms of Mumps**

[Illustration of young child with text and arrows pointing to various parts of the body]

Fever

Headaches

Swollen glands under the ears or jaw

Muscle aches

**Mumps is Contagious**

Here’s how it’s spread...

Coughing and sneezing

[Illustration of two people facing each other; one is coughing and sneezing, spraying particles]

Touching objects or surfaces with unwashed hands

[Illustration of particles on sippy cup and on hand touching the sippy cup]

**Measles in the United States**

From year to year, mumps cases in the U.S. range from roughly a couple hundred to a couple thousand.

[Graphic of U.S. map covered with dots]

**Protect Your Child**

The MMR vaccine protects against measles, mumps and rubella. Doctors recommend that your child get 2 doses of MMR for best protection. Your child will need one dose at each of the following ages...

Dose #1 at 12 through 15 months

Dose #2 at 4 through 6 years

**Immunization. Power to Protect**

Learn more at www.cdc.gov/vaccines/parents

**CDC logo, AAP logo, AAFP logo**

 Top of Page

November 23, 2016
National Center for Immunization and Respiratory Diseases
Exhibit 10.1


 


Information Concerning Executive Compensation


 


On June 27, 2014, the Compensation Committee of HomeFed Corporation (the "Company") approved annual salary increases (effective as of January 1, 2014) for each of the Company's executive officers who were included as named executive officers in the Company's 2014 proxy statement.









	
Name and Title

	
 

	
Base Salary in 2014


	
 

	
 

	
 


	
Paul J. Borden

	
 

	
$364,656


	
President and

	
 

	
 


	
Chief Executive Officer

	
 

	
 


	 		
	
John Kent Aden, Jr.

	
 

	
$298,342


	
Vice President

	
 

	
 


	
 

	
 

	
 


	
Christian E. Foulger

	
 

	
$229,294


	
Vice President

	
 

	
 


	
 

	
 

	
 


	
Erin N. Ruhe

	
 

	
$218,794


	
Vice President,

	
 

	
 


	
Treasurer and Controller
No. 11-5086.

#### Donald M. Reynolds, Petitioner v. United States.

565 U.S. 960, 132 S. Ct. 401,

181 L. Ed. 2d 288,

2011 U.S. LEXIS 7196.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.

Justice Kagan took no part in the consideration or decision of this petition.
PHYLLIS JENNINGS 

Is inducted into the Defense Industrial Supply Center Hall of Fame this twentieth day of January 

1999 for her extraordinary leadership and support as a Computer Specialist in the Office of 

Telecommunications and Information Systems and for her continuous outstanding mission support 

throughout her tenure at DISC from 1961 to 1993. 

Ms. Jennings was known for making suggestions to improve the quality of DISC in many ways. She 

was also involved in many other programs. She was a PROJECT GIVE (Government-Industry 

Volunteers for Education) tutor. But she took the time to help, mentor and encourage new 

employees to become acclimated. 

Hall of Fame Inductees Page 1 of 1

https://www.troopsupport.dla.mil/about_us/jennings.htm 1/21/2016
EXHIBIT 32.2


                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT 0F 2002

In connection with the Annual Report of PocketSpec Technologies Inc. (the
Company") on Form 10-KSB for the period ending January 31, 2004 as filed with
the Securities and Exchange Commission (the "Report"), I. Cynthia Kettl, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as
adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fully presents, in all
          material respects, the financial condition and results of operations
          or the Company.

SEPTEMBER 20, 2004

                                                     By: /s/  Cynthia Kettl
                                                     -------------------------
                                                     Chief Financial Officer











                                                                              17
# Registration_FOPOC Designation
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 06727

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2

File Name Description

06727\06727_Certification Statement.pdf Plant certification statement

x 06727\06727_Checklist.xls EPA Technical Review Checklist Workbook

06727\06727_Completeness_Checklist.xls EPA Completeness Review Checklist

06727\06727_HardcopyLog.doc EPA log of hardcopy documents submitted

x 06727\06727_PartA.xls Plant submitted survey file

x 06727\06727_PartB.xls Plant submitted survey file

x 06727\06727_PartC.xls Plant submitted survey file

x 06727\06727_PartD.xls Plant submitted survey file

x 06727\06727_PartE.xls Plant submitted survey file

x 06727\06727_PartH.xls Plant submitted survey file

06727\Supporting Documents\06727_Coverletter.pdf Cover letter

06727\Supporting Documents\06727_Map 1_Plant ID 6727.pdf Plant submitted supplemental files to the survey

x 06727\Supporting Documents\06727_Water-Balance_Plant ID 6727.pdf Plant submitted supplemental files to the survey

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

2

 Copyright documents are available from the docket.
*DoD 4000.25-1-M, January, 2006*

*Change 1*

*DLM 4000.25, Volume 2, November 26, 2019*

*Change 13*

**AP6.20. APPENDIX 6.20**

**FOLLOW-UP REQUEST FOR VALIDATION OF MATERIEL OBLIGATIONS(FMS AND GRANT AID TRANSACTIONS)(FROM ILCO to SAOs)**

AP6.20.1.  The referenced letter forwarded a listing (in duplicate) of MOV Request documents and a complete set of the documents (strike out one if not applicable) and requested that receipt be acknowledged.  This activity has no record of receiving the requested acknowledgment, nor any response to the validation requests.  Enclosed are duplicates/triplicates (strike out one) of listings for MOV Request documents and a complete set of the documents (strike out if not applicable).  The requests are submitted to your activity for validation of the continuing need for the item in the original requisition document.

AP6.20.2.  It is required that the item indicated by each validation request be reconciled with your records.  It is also required that each validation request be reviewed to determine the continuing need for the item and quantity shown.

AP6.20.3.  Annotate a copy of the enclosed listing/Data Block 8 and Block U of the remarks block, respectively, for each document to indicate:

(1)  The quantity of each item still required, and 

(2)  The quantity of each item received prior to receipt of the validation requests.  A copy of the annotated listing/the annotated documents (strike out one) should be transmitted by priority mail to this activity to arrive no later than enter date, which is 35 calendar days prior to the supply source response due date.

AP6.20.4.  Acknowledge receipt of the enclosed MOV Request documents by insertion of the date and signature below and return of the correspondence to the installation.

Enclosures

	1.  MOV Request documents

2.  Listing of Request documents (as applicable)

_____________________________________________________________________

(ACKNOWLEDGMENT OF RECEIPT)

_____________________________________________________________________

Above MOV Request documents were received

______________________________________

			(Date)

________________________

	(Signature)

***2***

APPENDIX 1.20

AP6AP6.20-1

APPENDIX 6.20
CDC’S TIPS FROM FORMER SMOKERS CAMPAIGN

Why It Matters to Dental Professionals

In its first year, CDC’s Tips From Former Smokers® 

(Tips®) campaign motivated 1.64 million smokers 

to try to quit. The Tips campaign continues this 

year with ads featuring people with a variety of 

smoking-related conditions and diseases and a 

national media buy. During the campaign, many 

of your patients will see and hear television, 

print, and digital messages from former smokers 

about the toll that smoking-related diseases can 

take. As a result, some of your smoking patients 

may think about quitting. They may seek your 

professional advice on how to get started. 

For those patients who are ready to quit, you 

can offer the motivation they need to become 

former smokers themselves. That’s why the Tips

campaign has resources to support dental professionals and their patients.

How Can I Use CDC’s Tips Campaign Resources to Help My Patients Quit?

• Explain how patients’ health conditions can be linked to smoking. Use the Tips campaign participants as examples. 

You can get to know the participants and read their personal stories at CDC.gov/tips.

• Suggest that your patients visit the 

How to Quit Smoking page of the 

Tips Web site.

• Check out the resources developed 

just for dental professionals. These 

include printable posters to hang in 

your waiting room and patient rooms, 

FAQs about quitlines, and a pocket card 

to help guide your conversations with 

patients.

• Let your patients know that they can get free quit help by calling 1-800-QUIT-NOW (1-800-784-8669) or 

1-855-DÉJELO-YA (1-855-335-3569) (for Spanish speakers).

Explore and share the resources CDC has 

available at CDC.gov/tips.

And like CDC Tobacco Free on Facebook today 

to keep informed.

U.S. Department of Health 

and Human Services 

Centers for Disease Control 

and Prevention

CDC.gov/tips